We understand, the sponsor has communicated your name, as one of the investigators for this multi-centric clinical study, to the Office of the Drugs Controller General (India), New Delhi.
Copy of the votes of the members of the IEC-Aditya who participated in the meeting are attached herewith for confirmation and record. Based on the favorable opinion given by all the 7 out of 7 members who participated in the meeting, Independent Ethics Committee -Aditya is pleased to grant approval to the conduct of the reviewed clinical study by you at, Dr. Harsh Toshniwal, IDTM Clinic, 402, Gala Business Centre, Near Rajhans Society, Saint Xavior's Commerce College Road, Off C.G. Road, AHMEDABAD 380 006, subject to the following conditions:
i. the clinical study will be conducted in full compliance to the regulatory directives indicated in the letter from the Office of the Drugs Controller General (India), New Delhi, ii.
the IEC-Aditya shall do a continuing review of the progress of the trial for which you shall provide periodic clinical updates on the progress of the study, iii.
the IEC-Aditya shall provide, according to the applicable regulatory requirements, expedited review and approval/favorable opinion on minor change(s) in the trial during the course of its conduct, if required, iv.
that no deviations from, or changes of, the protocol would be initiated without prior written IEC-Aditya approval/favorable opinion of an appropriate amendment. except when necessary to eliminate immediate hazards to the subjects or when the change(s) involves only logistical or administrative aspects of the trial (e.g., change ofmonitor(s), telephone number(s)) v.
that the investigator would promptly report to the IEC-Aditya : (a) deviations from, or changes in, the protocol to eliminate immediate hazards to the trial subjects, (b) changes increasing the risk to subjects and/or affecting significantly the conduct of the trial, (c) all adverse events including, serious and unexpected, and (d) new information that may adversely affect the safety of the subjects or the conduct of the trial, and vi.
that the IEC-Aditya would promptly notify in writing the investigator/institution concerning: (a) its trial-related decisions/opinions. (b) the reasons for its decisions/opinions, and (c) procedures for appeal on its decisions/opinions. 
